Subscribe To

Price Alert Latest News Economic Calendar News

NAVB / Navidea Biopharmaceuticals rejects ProPhase Labs offer

Navidea Biopharmaceuticals Inc. NAVB, -2.38% announced Friday that it had rejected an unsolicited ProPhase Labs Inc. PRPH, +0.08% offer for certain Navidea assets, saying the proposal undervalues Navidea and is not in the best interest of shareholders. ProPhase, a biotech, genomics and diagnostics company, said in a release Thursday that on June 8 it had offered $7 million in cash or $9.1 million in common stock for the assets, with the cash offer equivalent to over two times the then-current market cap of Navidea. Read More

Demo Live Account See Partner Details

Content Topics

Navidea

Biopharmaceuticals

Rejects

Prophase

Labs

Offer

Stock

NAVB

Posted: Jun 30 2023, 09:44

Author Name: Market Watch

NAVB News

By InvestorPlace
July 31, 2023

Why Is Navidea Biopharmaceutical (NAVB) Stock Down 13% Today?

Navidea Biopharmaceutical (NYSEMKT: NAVB ) stock is falling on Monday after the biopharmaceutical company got a major delisting warning. The NYSE Ame

By Market Watch
June 30, 2023

Navidea Biopharmaceuticals rejects ProPhase Labs offer

Navidea Biopharmaceuticals Inc. NAVB, -2.38% announced Friday that it had rejected an unsolicited ProPhase Labs Inc. PRPH, +0.08% offer for certain Na

By Seeking Alpha
March 21, 2023

Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2022 Earnings Call Transcript

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q4 2022 Earnings Conference Call March 22, 2023 5:00 PM ET Company Participants Michael Rosol - SVP & Ch

By Seeking Alpha
November 15, 2022

Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2022 Earnings Call Transcript

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q3 2022 Earnings Conference Call November 15, 2022 5:00 PM ET Company Participants Michael Rosol – Chi

By Seeking Alpha
September 8, 2022

Navidea Biopharmaceuticals, Inc. (NAVB) Q2 2022 Earnings Call Transcript

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q2 2022 Earnings Conference Call September 8, 2022 4:00 PM ET Company Participants Michael Rosol – CMO

By Business Wire
August 30, 2022

Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the developme

By Seeking Alpha
May 12, 2022

Navidea Biopharmaceuticals, Inc. (NAVB) Management on Q1 2022 Results - Earnings Call Transcript

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q1 2022 Results Conference Call May 12, 2022 5:00 PM ET Company Participants Michael Rosol - CMO Erika E

By Seeking Alpha
March 23, 2022

Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2021 Results - Earnings Call Transcript

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.